Good point, however, the company have reported activity to...

Good point, however, the company have reported activity to expand the technology for other cancers.

December 2022 - https://rhythmbio.com/file/1624/325?p=220

"Rhythm has further progressed its feasibility program now confirming a second bioanalytical partner, the
Baker Institute, who have been engaged to advance proof of concept for a second cancer program. The
Baker Institute is an independent, internationally renowned medical research facility, with a history
spanning more than 96 years, focusing on diagnosis, prevention and treatment of diabetes, cardiovascular
disease and associated metabolic diseases. The Company’s will focus on feasibility, testing and validation
of the biomarkers of interest identified by Rhythm."

Announcements to update progress could occur at any time...